GLOW: MRD Outcomes After First-line Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Older/Unfit Patients With CLL

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
Updated results from the phase III GLOW trial show that first-line, fixed-duration ibrutinib + venetoclax confers deep and prolonged undetectable MRD responses, leading to favorable PFS outcomes for older or unfit patients with CLL.
Format: Microsoft PowerPoint (.ppt)
File Size: 168 KB
Released: December 12, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings